Literature DB >> 33322961

Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy.

Winnie W Y Sung1, James C H Chow1, William C S Cho1.   

Abstract

Entities:  

Keywords:  Cancer immunotherapy; tissue-agnostic biomarker; tumor mutational burden

Mesh：

Substances：

Year:  2020        PMID： 33322961     DOI： 10.1080/17512433.2021.1865797

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN： 1751-2433            Impact factor:   5.045


× No keyword cloud information.
  3 in total

1.  Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review.

Authors:  K C Wilson; M P Flood; D Oh; N Calvin; M Michael; R G Ramsay; A G Heriot
Journal:  Ann Surg Oncol       Date:  2021-05-28       Impact factor: 5.344

2.  Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.

Authors:  Hao Wang; Shanhao Chen; Die Meng; Chunyan Wu; Junjie Zhu; Minlin Jiang; Jing Ning; Shengyu Wu; Lijia Wu; Jingjie Li; Bin Chen; Sha Zhao; Wei Li; Jia Yu; Qiyu Fang; Jun Zhu; Wencheng Zhao; Yayi He; Caicun Zhou
Journal:  Onco Targets Ther       Date:  2021-05-04       Impact factor: 4.147

3.  Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma.

Authors:  Ritu Shrestha; Kim R Bridle; Darrell H G Crawford; Aparna Jayachandran
Journal:  Int J Med Sci       Date:  2021-04-22       Impact factor: 3.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.